5-Amino-1MQ
Also known as: 5-amino-1-methylquinolinium
By GLPeptideSciences Editorial Team · How we evaluate evidence · Reviewed by Dr. George S. Watson, MD, Cardiothoracic Surgeon · Updated 2026-06-02
A small-molecule NNMT inhibitor studied in early metabolic research; technically not a peptide, but commonly grouped with metabolic compounds in the community.
What it is & how it works
What it is
5-Amino-1MQ is a small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme involved in fat-cell metabolism. Despite its placement here, it isn’t a peptide — the community simply discusses it among metabolic compounds.
How it is thought to work
Inhibiting NNMT is hypothesized to shift fat-cell energy metabolism in ways that, in animal models, affected adiposity. That’s the basis of the metabolic interest.
The evidence gap
The data is preclinical — cells and animals. Human efficacy and safety are unestablished, and the product is marketed well ahead of the evidence. Read fat-loss claims as unproven.
What it's discussed & studied for
- Metabolism and fat-cell biology (preclinical)
- Body composition (claimed; very early)
Discussion of a use is not a claim that it works or is approved.
Research status
Early preclinical research (cell and animal). No meaningful human trial evidence; not approved.
Evidence quality
Low. Findings are preclinical; human efficacy and safety are unestablished. Marketed well ahead of the evidence.
Dosing discussion
No human dosing is established. Community protocols are speculative.
Educational summary of what is discussed in the literature and community — not a dosing recommendation or medical advice.
Safety & harm reduction
Human safety is unknown given the lack of human studies. Not approved. Sourcing quality is the dominant practical risk.
Sourcing literacy
Sold as an oral 'metabolic' compound despite minimal human data. Treat efficacy claims as unproven and verify product identity/purity.
Selected literature
FAQ
Is 5-Amino-1MQ a peptide?
Not really — it's a small molecule (an NNMT inhibitor). It's grouped here because the community discusses it among metabolic compounds.
Is there human evidence?
No meaningful human trial evidence exists. The research is preclinical, and it is not approved.